Skip to main content
OpenTrials

Clinical trial condition

Post-polycythemia Vera Myelofibrosis

Explore clinical trials studying Post-polycythemia Vera Myelofibrosis. Study availability and eligibility vary by location and protocol.

24 public trials 9 recruiting studies
Refine in advanced search Browse all conditions

Post-polycythemia Vera Myelofibrosis trial results

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

NCT04173494

Conditions
Anemia, Bone Marrow Diseases, Hematologic Diseases, +5 more
Locations
  • Mayo Clinic Hospital - Phoenix Phoenix, Arizona, United States
  • Irvine Center for Clinical Research Irvine, California, United States
  • Norris Comprehensive Cancer Center Los Angeles, California, United States
  • American Institute of Research - Whittier Whittier, California, United States
View all 167 locations
View Trial Details
Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

NCT02124746

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +15 more
Locations
  • Scottsdale, Arizona, United States
  • Orange, California, United States
  • Stanford, California, United States
  • Whittier, California, United States
View all 22 locations
View Trial Details
Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

NCT04884191

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
View all 62 locations
View Trial Details
Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

NCT01423851

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +14 more
Locations
  • Mayo Clinic Scottsdale Recruiting Scottsdale, Arizona, United States
  • UC San Diego Moores Cancer Center San Diego, California, United States
  • Mayo Clinic, Jacksonville Jacksonville, Florida, United States
  • Northwestern University Chicago, Illinois, United States
View Trial Details
Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details
Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT00935987

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +4 more
Locations
  • Stanford Cancer Center Stanford, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • The Royal Melbourne Hospital Parkville, Victoria, Australia
View Trial Details

Related conditions